Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

September 27, 2019 12:32 AM UTC

Neurogene Inc. hired Christine Mikail as president. She is a co-founder of neurology specialty pharma Neumentum Inc. and biotech consulting firm Ferndale Advisors. Neurogene is developing disease-modifying gene therapies for two monogenic, pediatric disorders in which enzyme replacement is not feasible or hasn’t been explored (see “Genes Over ERT for Monogenic CNS Diseases”).

HemoShear Therapeutics LLC, which is focused on metabolic disorders, hired Brian Johns as CSO. Johns was VP, external discovery sciences at ViiV Healthcare Ltd., which is majority owned by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). While at GSK, he co-discovered the HIV antiviral Tivicay dolutegravir. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article